XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA ...
What guidance does management provide on earnings per share (EPS) and dividend policy after the acquisition?
How will this acquisition influence XOMA’s long‑term strategic positioning in the royalty‑based biotech investment space?
Are there any regulatory or antitrust considerations that could delay or alter the transaction?
17 days ago